Register Login

EDWARDS LIFESCIENCES CORP (EW)

Director Zovighian Bernard J 🟡 adjusted position in 323.3K shares (2 derivative) of Edwards Lifesciences Corp (EW) at $83.20 ($21.1M) Transaction Date: May 07, 2026 | Filing ID: 005131

Full text
Register to leave comments
  • News bot May 12, 2026, 1:33 a.m.

    🔍 Zovighian Bernard J (Director)

    Company: Edwards Lifesciences Corp (EW)

    Report Date: 2026-05-07

    Transaction Summary:

    • Total transactions: 10
    • Derivative instruments: 2
    • Holdings reported: 1
    • Total shares acquired: 342,611
    • Total shares sold: 19,262
    • Total shares held: 3,734

    Detailed Transactions and Holdings:

    • Acquired 43,800 shares of Common Stock (Direct)
      Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 124,057.65 | transaction_form_type: 4 | Footnotes: F1
    • Sold 4,153 shares of Common Stock at $83.2 per share (Direct)
      Date: 2026-05-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 119,904.65 | transaction_form_type: 4
    • Sold 4,222 shares of Common Stock (Direct)
      Date: 2026-05-08 | Code: G | equity_swap_involved: 0 | shares_owned_after: 115,682.65 | transaction_form_type: 4
    • Sold 5,398 shares of Common Stock at $82.76 per share (Direct)
      Date: 2026-05-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 110,284.65 | transaction_form_type: 4
    • Sold 5,489 shares of Common Stock (Direct)
      Date: 2026-05-11 | Code: G | equity_swap_involved: 0 | shares_owned_after: 104,795.65 | transaction_form_type: 4
    • Acquired 4,222 shares of Common Stock (Direct)
      Date: 2026-05-08 | Code: G | equity_swap_involved: 0 | shares_owned_after: 16,261.55 | transaction_form_type: 4
    • Acquired 5,489 shares of Common Stock (Direct)
      Date: 2026-05-11 | Code: G | equity_swap_involved: 0 | shares_owned_after: 21,750.55 | transaction_form_type: 4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-05-07 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 3,733.56
    • Acquired 245,300 shares of Employee Stock Option (Right to Acquire) at $82.76 per share (Derivative)
      Date: 2026-05-07 | Code: A | Expires: 2033-05-06 | Exercise: 2027-05-07 | equity_swap_involved: 0 | shares_owned_after: 245,300.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 43,800 shares of Performance Rights (Derivative)
      Date: 2026-05-07 | Code: A | Exercise: 2029-05-07 | equity_swap_involved: 0 | shares_owned_after: 43,800.00 | transaction_form_type: 4 | Footnotes: F3, F3

    Footnotes:

    • F1: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
    • F2: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
    • F3: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
    • REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Search

News categories